Ovarian lymphoma

The involvement of the ovary in lymphomatous processes is rare. Such an involvement can occur in 2 ways, either primary or secondary, which usually presents with abdominal or pelvic complaints. We present a case of secondary involvement of the ovary with occult extra-ovarian nodal disease and discuss the histogenesis of ovarian lymphomas with criteria for diagnosis and differential diagnosis

Significance of preoperative thrombocytosis in epithelial ovarian cancer

<b>Background:</b> Reactive thrombocytosis is reported in a variety of solid tumors. A few studies have documented preoperative thrombocytosis in ovarian cancer and identified it as a marker of aggressive tumor biology. <b>Aim:</b> To study the incidence of preoperative thrombocytosis (platelets greater than 400x10) in epithelial ovarian cancer and its association with other clinicopathologic factors. <b> Materials and Methods:</b> Sixty-five patients with invasive ovarian epithelial cancer were retrospectively reviewed and analyzed for the association preoperative thrombocytosis with other clinical and histopathological prognostic factors. Means were analyzed by Student&#x2032;s t test; proportions were determined by Chi-square analysis. <b> Results:</b> Twenty of 65 (37.5&#x0025;) patients had thrombocytosis at primary diagnosis. Patients with preoperative thrombocytosis were found to have lower hemoglobin (P &lt; 0.0002), more advanced stage disease (P &lt; 0.05) and higher grade tumors (P &lt; 0.02). Patients with thrombocytosis had greater likelihood of subpotimal cytoreduction. <b> Conclusions:</b> Preoperative thrombocytosis is a frequent finding in ovarian carcinomas and their association with advanced stage disease and higher grade denotes that platelets play a role in the tumor growth and progression

Estrogen and Progesterone Receptor Expression in Endometrioid Endometrial Carcinomas: A Clinicopathological Study

Background: This study assesses the expressions of estrogen and progesterone receptors in endometrioid carcinomas of the endometrium and their association with established clinicopathological prognostic parameters. Methods: We reviewed the pathology and medical records from 45 cases of endometrioid endometrial carcinomas that were seen from 2006 to 2011 for relevant clinical and histological parameters. Grade I and stage IA tumors were analyzed and compared with higher grades and stages IB- IV. Estrogen and progesterone immunostained slides were analyzed. Results: Patients’ age ranged from 32 to 77 years (mean: 58.13 years). Postmenopausal bleeding was the most common presenting complaint seen in 75.6% of cases. Associated co-morbidities such as diabetes, hypertension and other malignancies were seen in 88% of cases. Myometrial invasion of less than 50% of myometrial thickness was seen in 70.5% cases. There were 40% of tumors classified as FIGO grade 1 and 65.85% were FIGO stage IA. Estrogen and progesterone expressions were seen in 40 (90%) cases, predominantly in FIGO stage I disease. However there was no statistically significant association of estrogen and progesterone expression with any of the clinicopathological prognostic factors. In 23 of the 30 cases that had follow up data, there was no evidence of disease. Of these, only one case was negative for both hormone receptors. Progesterone positivity alone was seen in 87% of cases with no evidence of disease. Conclusions: Nuclear immunostaining with estrogen and progesterone was seen in the majority of cases (90%). Although we have observed a linear increase in progesterone receptor positivity with disease-free survival, this finding needs to be confirmed with additional, larger studies

Decreased Survival With Mastectomy Vis-à-Vis Breast-Conserving Surgery in Stage II and III Breast Cancers: A Comparative Treatment Effectiveness Study

Purpose: The primary purpose of hospital-based cancer registries is assessing patient care. Clinical stage–based survival and treatment-based survival are some of the key parameters for such assessment. Because of the challenges in obtaining follow-up parameters, a separate study on patterns of care and survival was undertaken by the Indian National Cancer Registry Program. The results for cancer of the female breast are presented here. Patients and Methods: Data abstracted in a standardized patient information form were transmitted online to a central repository. Treatment patterns were assessed for 9,903 patients diagnosed between January 1, 2006, and December 31, 2008, from 13 institutions. Survival analysis was restricted to 7,609 patients from nine institutions wherein follow-up details (as of December 31, 2012) were available for at least 60% of patients. Results: The overall 5-year survival rates with breast-conserving surgery (BCS) and mastectomy (MS) were 94.0% and 85.8%, respectively, for stage II disease (adjusted hazard ratio, 2.40; 95% CI, 1.8 to 3.2) and 87.1% and 69.0%, respectively, for stage III disease (hazard ratio, 2.82; 95% CI, 2.2 to 3.7). Patients who had MS did better with systemic therapy (chemotherapy and/or hormone therapy), whereas patients with BCS required just local radiation therapy to achieve best survival. Conclusion: This observational study in the natural setting of care of patients with cancer in India showed significantly decreased survival with MS when compared with BCS. The reasons for lower survival with MS and the biologic or scientific rationale of the necessity of systemic therapy to achieve optimal survival in patients undergoing MS but not in those with BCS need further investigation